5-Amino-1MQ
Monograph · D5-Amino-1MQ
Small-molecule NNMT inhibitor (not a peptide). Blocks nicotinamide N-methyltransferase to preserve cellular methyl-donor pools and NAD+.
How it clearsHalf cleared in ~6h. Most (~96%) gone by ~1d.
Compare these compounds
Mechanism, evidence, legal path, cost — all side-by-side.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Tracked alongside peptides in biohacker stacks. Preclinical models show reduced adipose hypertrophy and improved muscle stem-cell function. No human RCTs published. Different chemistry from peptides — included here because it shows up in the same protocols.
Early-stage — most claims are extrapolated from animal or in-vitro studies with no human replication at scale. Longevity effects specifically resist short-term human measurement, which means both positive and negative signals are genuinely difficult to read.
Not a peptide; included for stack context. Zero published human trials. Long-term safety unknown.
Upload your data to see how it relates to 5-Amino-1MQ.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyPer-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- DMechanistic / anecdotal
5-Amino-1MQ inhibits NNMT in rodent metabolic studies
1 supporting referencesVerified 23d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Handoff & sources
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.